Epilepsy is a common neurological disorder characterised by recurring, unprovoked seizures. There is no definitive diagnostic test and waits for diagnosis can be long. Earlier diagnosis allows for quicker initiation of treatment and reduces the risk of hospital admissions.
Nelli® is a remote monitoring device that allows patients to be monitored at home. The device consists of a small camera on a stand which records patients while they are asleep or resting. These recordings are then analysed by AI, which identifies and classifies seizures enabling clinicians to accurately diagnose the patient and prescribe appropriate treatment.
HIOTV carried out a full real-world evaluation to generate the evidence required for a business case to support the adoption and spread of Nelli in the epilepsy diagnosis pathway within the NHS in England. In addition, HIOTV worked with York Health Economics Consortium (YHEC) to create a health economics model to support further potential adoption. The Environment Sustainability Lead for the Kent Surrey Sussex and Oxford and Thames Valley Health Innovation Networks is also establishing the carbon footprint reduction related to this innovation.
This was funded as part of a joint grant application (with NeuroEvent Labs, Oxford University Hospitals (OUH) NHS Foundation Trust and The Royal Wolverhampton NHS Trust) from NHSx, now the NHS Transformation Directorate. The two NHS trusts which took part in the service evaluation are creating business cases to support the procurement of the technology – and there is also interest from other NHS trusts.
